CoChat

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

Open access
Scott, Jack D., DeMong, Duane E., Greshock, Thomas J., Basu, Kallol, Dai, Xing, Harris, Joel, Hruza, Alan, Li, Sarah W., Lin, Sue-Ing, Liu, Hong, Macala, Megan K., Hu, Zhiyong, Mei, Hong, Zhang, Honglu, Walsh, Paul, Poirier, Marc, Shi, Zhi-Cai, Xiao, Li, Agnihotri, Gautam, Baptista, Marco A. S., Columbus, John, Fell, Matthew J., Hyde, Lynn A., Kuvelkar, Reshma, Lin, Yinghui, Mirescu, Christian, Morrow, John A., Yin, Zhizhang, Zhang, Xiaoping, Zhou, Xiaoping, Chang, Ronald K., Embrey, Mark W., Sanders, John M., Tiscia, Heather E., Drolet, Robert E., Kern, Jonathan T., Sur, Sylvie M., Renger, John J., Bilodeau, Mark T., Kennedy, Matthew E., Parker, Eric M., Stamford, Andrew W., Nargund, Ravi, McCauley, John A., Miller, Michael W. · 2017 · Journal of Medicinal Chemistry
Cited by 143

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Leucine-rich repeat kinase 2 (LRRK2) is a large, multidomain protein which contains a kinase domain and GTPase domain among other regions. Individuals possessing gain of function mutations in the kinase domain such as the most prevalent G2019S mutation have been associated with an increased risk for the development of Parkinson's disease (PD). Given this genetic validation for inhibition of LRRK2 kinase activity as a potential means of affecting disease progression, our team set out to develop LRRK2 inhibitors to test this hypothesis. A high throughput screen of our compound collection afforded a number of promising indazole leads which were truncated in order to identify a minimum pharmacophore. Further optimization of these indazoles led to the development of MLi-2 (1): a potent, highly selective, orally available, brain-penetrant inhibitor of LRRK2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b00045

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 143

Metadata

Authors
Scott, J. D., DeMong, D. E., Greshock, T. J., Basu, K., Dai, X., Harris, J., Hruza, A., Li, S. W., Lin, S.-I., Liu, H., Macala, M. K., Hu, Z., Mei, H., Zhang, H., Walsh, P., Poirier, M., Shi, Z.-C., Xiao, L., Agnihotri, G., Baptista, M. A. S., Columbus, J., Fell, M. J., Hyde, L. A., Kuvelkar, R., Lin, Y., Mirescu, C., Morrow, J. A., Yin, Z., Zhang, X., Zhou, X., Chang, R. K., Embrey, M. W., Sanders, J. M., Tiscia, H. E., Drolet, R. E., Kern, J. T., Sur, S. M., Renger, J. J., Bilodeau, M. T., Kennedy, M. E., Parker, E. M., Stamford, A. W., Nargund, R., McCauley, J. A., & Miller, M. W.
Venue
Journal of Medicinal Chemistry
Published
2017-03-16
Volume
60
Issue
7
Pages
2983-2992
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2593373447
Cited by
143
References
3
FWCI
8.62
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b00045
The paper
Scott, J. D., DeMong, D. E., Greshock, T. J., Basu, K., Dai, X., Harris, J., Hruza, A., Li, S. W., Lin, S.-I., Liu, H., Macala, M. K., Hu, Z., Mei, H., Zhang, H., Walsh, P., Poirier, M., Shi, Z.-C., Xiao, L., Agnihotri, G., . . . Miller, M. W. (2017). Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b00045

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.